ICD-10: C82.07

ICD-10 code C82.07 specifically refers to "Follicular lymphoma, grade I, spleen." This classification falls under the broader category of non-Hodgkin lymphoma, which encompasses various types of lymphomas characterized by the malignant transformation of lymphoid tissue. Below are alternative names and related terms associated with this specific diagnosis.

Alternative Names for Follicular Lymphoma Grade I

1. Follicular Lymphoma, Low-Grade: This term emphasizes the indolent nature of grade I follicular lymphoma, which typically has a slower progression compared to higher-grade lymphomas.

2. Follicular Lymphoma, Stage I: While not a direct synonym, this term may be used in clinical contexts to describe the localized nature of the disease when it primarily affects the spleen.

3. Indolent Follicular Lymphoma: This term highlights the slow-growing characteristics of grade I follicular lymphoma, distinguishing it from more aggressive forms of lymphoma.

4. Spleen Follicular Lymphoma: This term specifies the anatomical location of the lymphoma, indicating that the spleen is the primary site of involvement.

Related Terms

1. Non-Hodgkin Lymphoma (NHL): Follicular lymphoma is a subtype of non-Hodgkin lymphoma, which is a diverse group of blood cancers that includes various lymphoid malignancies.

2. Lymphoid Tissue: This term refers to the tissues involved in the immune response, including lymph nodes, spleen, and bone marrow, where follicular lymphoma can originate.

3. B-cell Lymphoma: Follicular lymphoma is classified as a B-cell lymphoma, as it arises from B-lymphocytes, a type of white blood cell.

4. Lymphoma, Follicular Type: This term is often used interchangeably with follicular lymphoma and may refer to both grade I and higher-grade variants.

5. Chronic Lymphocytic Leukemia (CLL): While distinct, CLL can sometimes be confused with follicular lymphoma due to overlapping features in lymphocyte proliferation.

6. Lymphoma Staging: This refers to the process of determining the extent of lymphoma spread, which is crucial for treatment planning and prognosis.

Conclusion

Understanding the alternative names and related terms for ICD-10 code C82.07 is essential for accurate diagnosis, treatment planning, and communication among healthcare professionals. Follicular lymphoma, particularly grade I, is characterized by its indolent nature and specific anatomical involvement, which can influence management strategies. If you need further information on treatment options or prognosis related to this condition, feel free to ask!

Follicular lymphoma is a type of non-Hodgkin lymphoma characterized by the proliferation of follicle center (germinal center) B-cells. The ICD-10-CM code C82.07 specifically refers to Follicular lymphoma grade I located in the spleen. Below is a detailed clinical description and relevant information regarding this diagnosis.

Clinical Description of Follicular Lymphoma Grade I

Definition and Characteristics

Follicular lymphoma is classified as a low-grade lymphoma, which means it typically grows slowly compared to high-grade lymphomas. Grade I follicular lymphoma is characterized by a predominance of small, cleaved cells (also known as centrocytes) and is often associated with a more favorable prognosis compared to higher grades of follicular lymphoma. The disease is usually indolent, meaning that it may not require immediate treatment and can often be monitored over time.

Pathophysiology

Follicular lymphoma arises from the B-cells in the lymphatic system, particularly from the germinal centers of lymphoid follicles. The neoplastic transformation of these cells often involves chromosomal translocations, most commonly the t(14;18) translocation, which leads to the overexpression of the BCL2 gene, inhibiting apoptosis and allowing for the accumulation of malignant cells.

Symptoms

Patients with follicular lymphoma may present with:
- Painless lymphadenopathy (swollen lymph nodes)
- Splenomegaly (enlargement of the spleen), which is specifically noted in cases coded as C82.07
- Fatigue
- Unexplained weight loss
- Night sweats
- Fever

Diagnosis

Diagnosis typically involves:
- Histopathological examination: A biopsy of the affected lymph node or spleen is essential for confirming the diagnosis and determining the grade of the lymphoma.
- Immunophenotyping: This process helps to identify the specific markers on the lymphoma cells, confirming their B-cell origin.
- Imaging studies: CT scans or PET scans may be used to assess the extent of the disease and involvement of other lymphoid tissues.

Treatment Options

Treatment for follicular lymphoma grade I may vary based on the stage of the disease and the patient's overall health. Common approaches include:
- Watchful waiting: In cases where the lymphoma is asymptomatic and indolent, active monitoring may be preferred.
- Chemotherapy: Regimens such as R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) may be used for symptomatic patients.
- Immunotherapy: Rituximab, a monoclonal antibody targeting CD20 on B-cells, is often used in treatment.
- Radiation therapy: This may be considered for localized disease or for palliation of symptoms.

Prognosis

The prognosis for patients with follicular lymphoma grade I is generally favorable, with many patients living for years without significant symptoms. However, the disease can transform into a more aggressive form, necessitating closer monitoring and potential treatment adjustments.

Conclusion

ICD-10 code C82.07 encapsulates the clinical nuances of follicular lymphoma grade I affecting the spleen. Understanding the characteristics, symptoms, diagnostic methods, and treatment options is crucial for effective management and patient care. Regular follow-up and monitoring are essential to address any changes in the disease's behavior over time.

Follicular lymphoma, particularly grade I, is a type of non-Hodgkin lymphoma characterized by its indolent nature and specific clinical presentations. The ICD-10 code C82.07 refers specifically to follicular lymphoma grade I located in the spleen. Understanding the clinical presentation, signs, symptoms, and patient characteristics associated with this condition is crucial for diagnosis and management.

Clinical Presentation

General Characteristics

Follicular lymphoma is a hematological malignancy that arises from B-lymphocytes, typically presenting as a slow-growing tumor. Grade I indicates a low proliferation rate, which often correlates with a more favorable prognosis compared to higher-grade lymphomas. The spleen can be involved either primarily or secondarily, leading to various clinical manifestations.

Signs and Symptoms

Patients with follicular lymphoma grade I affecting the spleen may exhibit a range of signs and symptoms, including:

• Lymphadenopathy: Swelling of lymph nodes is common, although splenic involvement may not always present with peripheral lymphadenopathy.
• Splenomegaly: Enlargement of the spleen is a hallmark of this condition, often leading to abdominal discomfort or a feeling of fullness.
• Fatigue: Patients frequently report persistent fatigue, which can be attributed to the disease process or anemia.
• Weight Loss: Unintentional weight loss may occur, often due to the systemic effects of the lymphoma.
• Night Sweats: Patients may experience drenching night sweats, a common symptom in various lymphomas.
• Fever: Low-grade fevers can be present, contributing to the overall malaise.
• Abdominal Pain or Discomfort: This may arise from splenomegaly or associated lymphadenopathy in the abdomen.

Patient Characteristics

Certain demographic and clinical characteristics are often observed in patients diagnosed with follicular lymphoma grade I:

• Age: The condition is more prevalent in older adults, typically diagnosed in individuals aged 60 and above.
• Gender: There is a slight male predominance in the incidence of follicular lymphoma.
• Comorbidities: Patients may have other health conditions, such as autoimmune diseases, which can complicate the clinical picture.
• Family History: A family history of lymphoproliferative disorders may be noted in some patients, suggesting a potential genetic predisposition.

Diagnostic Considerations

Diagnosis of follicular lymphoma grade I involves a combination of clinical evaluation, imaging studies, and histopathological examination. Key diagnostic tools include:

• Imaging: Ultrasound or CT scans may be used to assess splenic size and detect any lymphadenopathy.
• Biopsy: A definitive diagnosis is made through a biopsy of the affected lymph node or spleen tissue, which reveals the characteristic follicular architecture and low-grade features.
• Immunophenotyping: Flow cytometry or immunohistochemistry can help confirm the B-cell lineage and the presence of specific markers associated with follicular lymphoma.

Conclusion

Follicular lymphoma grade I, particularly when involving the spleen, presents with a unique set of clinical features that can guide diagnosis and management. Recognizing the signs and symptoms, along with understanding patient demographics, is essential for healthcare providers in delivering effective care. Early diagnosis and appropriate treatment can significantly impact patient outcomes, emphasizing the importance of awareness and vigilance in clinical practice.

Follicular lymphoma, particularly grade I, is a type of non-Hodgkin lymphoma characterized by specific diagnostic criteria. The ICD-10 code C82.07 specifically refers to follicular lymphoma grade I located in the spleen. Here’s a detailed overview of the criteria used for diagnosis:

Diagnostic Criteria for Follicular Lymphoma Grade I

1. Clinical Evaluation

• Symptoms: Patients may present with symptoms such as painless lymphadenopathy, splenomegaly, or systemic symptoms like fever, night sweats, and weight loss. However, many patients may be asymptomatic at diagnosis[3].
• Physical Examination: A thorough physical examination is essential to assess for lymphadenopathy and splenomegaly, which are common findings in follicular lymphoma[3].

2. Histopathological Examination

• Biopsy: A biopsy of the affected lymph node or spleen is crucial. The histological examination typically reveals a proliferation of follicle center (germinal center) B-cells. The presence of small cleaved cells and a predominance of follicular structures is characteristic of grade I follicular lymphoma[3].
• Grading: Follicular lymphoma is graded based on the number of large cells (centroblasts) per high-power field (HPF). Grade I is defined as having fewer than 5 centroblasts per HPF[3].

3. Immunophenotyping

• Flow Cytometry: Immunophenotyping through flow cytometry is used to confirm the B-cell lineage of the lymphoma. The typical immunophenotype includes positive markers such as CD19, CD20, and CD10, along with negative markers like CD5 and CD23[3].
• BCL2 Gene Rearrangement: The presence of BCL2 gene rearrangement is a hallmark of follicular lymphoma and can be assessed through molecular techniques, further supporting the diagnosis[3].

4. Imaging Studies

• CT or PET Scans: Imaging studies such as computed tomography (CT) or positron emission tomography (PET) scans are often employed to assess the extent of disease, including the involvement of the spleen and other lymphatic tissues[3].

5. Staging

• Ann Arbor Staging System: The Ann Arbor staging system is used to determine the extent of the disease, which is crucial for treatment planning. Stage I indicates involvement of a single lymph node region or a single extralymphatic site, which may include the spleen[3].

6. Exclusion of Other Conditions

• Differential Diagnosis: It is important to rule out other conditions that may mimic follicular lymphoma, such as reactive lymphadenopathy or other types of lymphoma. This may involve additional laboratory tests and clinical correlation[3].

Conclusion

The diagnosis of follicular lymphoma grade I, particularly in the spleen, involves a comprehensive approach that includes clinical evaluation, histopathological examination, immunophenotyping, imaging studies, and staging. Accurate diagnosis is essential for effective treatment planning and management of the disease. If you have further questions or need more specific information, feel free to ask!

Follicular lymphoma, particularly grade I, is a type of non-Hodgkin lymphoma characterized by slow growth and a generally favorable prognosis. The ICD-10 code C82.07 specifically refers to follicular lymphoma grade I located in the spleen. Treatment approaches for this condition can vary based on several factors, including the patient's overall health, the extent of the disease, and individual preferences. Below, we explore the standard treatment modalities for follicular lymphoma grade I.

Standard Treatment Approaches

1. Watchful Waiting (Active Surveillance)

For patients with asymptomatic follicular lymphoma grade I, especially those with limited disease, a common approach is watchful waiting. This strategy involves regular monitoring without immediate treatment, as many patients may not require intervention for years. This approach is particularly suitable for older patients or those with other significant health issues.

2. Chemotherapy

When treatment is necessary, chemotherapy is often the first-line option. Common regimens include:

• CHOP Regimen: This includes Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. It is a standard treatment for various types of non-Hodgkin lymphoma.
• R-CHOP: This is a variation of the CHOP regimen that includes Rituximab, a monoclonal antibody that targets CD20 on B-cells, enhancing the effectiveness of chemotherapy.

3. Immunotherapy

Rituximab is frequently used in combination with chemotherapy for follicular lymphoma. It can also be used as a standalone treatment for patients who are not candidates for chemotherapy or those with relapsed disease. Other newer immunotherapies, such as Obinutuzumab, may also be considered.

4. Radiation Therapy

Radiation therapy may be employed in specific cases, particularly for localized disease or to alleviate symptoms. It is less common as a primary treatment for advanced follicular lymphoma but can be effective in managing localized areas of disease.

5. Stem Cell Transplantation

For patients with relapsed or refractory follicular lymphoma, high-dose chemotherapy followed by autologous stem cell transplantation may be an option. This approach is typically reserved for younger patients or those with aggressive disease features.

6. Targeted Therapy

Targeted therapies, such as PI3K inhibitors (e.g., Copanlisib) and BTK inhibitors, are emerging options for patients with relapsed follicular lymphoma. These therapies focus on specific pathways involved in cancer cell growth and survival, offering a more tailored treatment approach.

Conclusion

The management of follicular lymphoma grade I, particularly in the spleen, is multifaceted and should be personalized based on the patient's clinical scenario. While watchful waiting may be appropriate for some, others may require chemotherapy, immunotherapy, or even stem cell transplantation depending on disease progression and patient health. Ongoing research continues to refine these treatment strategies, aiming to improve outcomes and quality of life for patients with this type of lymphoma. Regular follow-up and monitoring are essential to adapt treatment plans as needed.